Allakos Stock Forecast, Price & News

Allakos (NASDAQ:ALLK) Frequently Asked Questions

Is Allakos a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Allakos stock.
View analyst ratings for Allakos or view top-rated stocks.

How has Allakos' stock been impacted by Coronavirus?

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLK stock has increased by 35.5% and is now trading at $79.00.
View which stocks have been most impacted by COVID-19.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Allakos.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Monday, November, 8th. The company reported ($1.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.12) by $0.04.
View Allakos' earnings history.

What price target have analysts set for ALLK?

6 brokerages have issued 12 month target prices for Allakos' stock. Their forecasts range from $76.53 to $230.00. On average, they expect Allakos' stock price to reach $151.11 in the next year. This suggests a possible upside of 91.3% from the stock's current price.
View analysts' price targets for Allakos or view top-rated stocks among Wall Street analysts.

Who are Allakos' key executives?

Allakos' management team includes the following people:

• Robert Alexander, Chief Executive Officer & Director
• Adam L. Tomasi, President & Chief Operating Officer (LinkedIn Profile)
• Harlan Baird Radford, Chief Financial Officer
• Craig Paterson, Chief Medical Officer
• Ruby Casareno, Vice President-Technical Operations

Who are some of Allakos' key competitors?

Some companies that are related to Allakos include BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Elanco Animal Health (ELAN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Legend Biotech (LEGN), Jazz Pharmaceuticals (JAZZ) and Grifols (GRFS).
View all of ALLK's competitors.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by many different institutional and retail investors. Top institutional investors include Capital World Investors (12.18%), Capital Research Global Investors (9.04%), Wellington Management Group LLP (7.03%), BlackRock Inc. (5.25%), Janus Henderson Group PLC (1.81%) and Alliancebernstein L.P. (1.25%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends for Allakos.

Which institutional investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, BlackRock Inc., Point72 Asset Management L.P., Two Sigma Investments LP, Morgan Stanley, Handelsbanken Fonder AB, Voloridge Investment Management LLC, and Two Sigma Advisers LP. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More, and Steven P James.
View insider buying and selling activity for Allakos or view top insider-selling stocks.

Which institutional investors are buying Allakos stock?

ALLK stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, ArrowMark Colorado Holdings LLC, Wellington Management Group LLP, Alliancebernstein L.P., Caption Management LLC, Jennison Associates LLC, Capital World Investors, and Goldman Sachs Group Inc..
View insider buying and selling activity for Allakos or or view top insider-buying stocks.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $79.00.

How much money does Allakos make?

Allakos has a market capitalization of $4.29 billion. The company earns $-153.48 million in net income (profit) each year or ($4.13) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 125 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

Where are Allakos' headquarters?

Allakos is headquartered at 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 597-5002 or via email at [email protected].